| |
|
| NCIC Clinical Trials Group / Cancer Clinical Trials Faculty Biographies |
| |
| Ralph Meyer, MD, FRCP(C) |
| Director |
| Dr. Meyer assumed the role of Director, NCIC CTG in April, 2007. He holds the Edith and Carla Eisenhauer Chair in Clinical Cancer Research and is Professor in the Departments of Oncology, Medicine and Community Health and Epidemiology at Queen's University. As Director of the NCIC CTG, Dr. Meyer has responsibilities for ensuring the quality of its scientific agenda and operational processes and also takes an active part in the development, execution and analysis of many of the Group's trials. His own research interests are in the hematologic malignancies and in the generation of clinical trials evidence for use in health care policies. Dr. Meyer was previously based at McMaster University from 1984 – 2006 where he was Director of Division of Hematology and Professor in the Department of Medicine, and Head, Hematology Malignancy Program at the Juravinski Cancer Centre. He has been a previous chair of the NCIC CTG’s Hematology Disease Site Committee. |
|
 |
|
| |
| Elizabeth Eisenhauer, MD, FRCP(C) |
| Director IND |
 |
|
Dr. Eisenhauer obtained her MD from Queen's University 1976 and subsequently completed training in both Internal Medicine and Hematology. In 1982 she became Director of the Investigational New Drug Program (IND) of the NCIC CTG where her major responsibilities lie in identifying and bringing into clinical trial novel cancer agents. She has coordinated over 150 phase I, II and III trials carried out in institutions in Canada, the US and Europe, including some of the first trials of paclitaxel and docetaxel, studies of topotecan, gemcitabine, various targeted antisense agents and small molecule signaling inhibitors. She is a Professor in the Department of Oncology at Queen's University. Her major research interest has been the evaluation of new anti-cancer agents. In 2002 she was appointed to the Board of Directors of the Canadian Cancer Society Research Institue, in 2004 was elected as Vice-President of the NCIC and in 2006 appointed President. In September 2008, Dr. Eisenhauer was appointed Chair of the The Canadian Partnership Against Cancer's Research Action Group and Co-Chair of the Canadian Cancer Research Alliance. |
|
| |
| Penny Bradbury, MB, BCh, FRACP, MD |
| Physician Coordinator |
| Dr. Bradbury is a medical oncologist; Assistant Professor within the Department of Oncology at Queen’s University and holds a Cancer Care Ontario Research Chair in Experimental Therapeutics. She is a graduate of Cardiff University Medical School, UK. She undertook specialist medical oncology training at the MidCentral Regional Cancer Treatment Service in New Zealand, and at the Cancer Research UK Medical Oncology Department, Churchill Hospital, Oxford, UK, obtaining the FRACP in 2005. She undertook fellowship training in Thoracic Oncology at Princess Margaret Hospital, Toronto, and a one year Drug Development Fellowship with the NCIC Clinical Trials Group, as part of The Terry Fox Foundation Training Program in Transdisciplinary Cancer Research at Canadian Institutes of Health Research. She has a research interest in the evaluation of new therapies for the management of thoracic malignancies and clinical trial methodology. Within the NCIC CTG, she is the physician coordinator for the lung disease site and for National and International thoracic malignancy clinical trials. |
|
 |
|
| |
| Judith-Anne W. Chapman, BSc, PhD, LFIBA, IOM, PStat, ON |
| Senior Biostatistician |
 |
|
Dr. Chapman received her PhD in Statistics (Biometry) from the University of Waterloo (1974); and, did 3 years postdoctoral training, 2 as a Research Fellow of the NCIC. She worked in the teaching hospitals of the University of Toronto, and held an adjunct research appointment at the University of Waterloo from 1999-2005 before joining the NCIC CTG as Senior Biostatistician and the Department of Community Health and Epidemiology at Queen's. She specializes in transdisciplinary breast cancer research proposing statistical standardization of hormone receptor values, improvements for cancer survival analyses, and new genome era tumour sample size considerations. Professionally, she spearheaded the formation of the Biostatistics Section of the Statistical Society of Canada (SSC), oversaw the implementation of SSC Accreditation of Professional Statisticians,and serves on the American Statistical Association Ad Hoc Committee to Propose an Approach to Individual Accreditation. |
|
| |
| Bingshu Chen, MSc, PhD |
| Senior Biostatistician |
| Dr. Chen joined the NCIC CTG as senior biostatistician and faculty member with the Department of Community Health and Epidemiology at Queen's University in July 2008. Dr. Chen completed his PhD at the University of Waterloo, then spent 4 years at the US National Cancer Institute in the Division of Cancer Epidemiology and Genetics, first as a Postdoctoral Fellow and then as a Research Fellow. He has spent the last year as an Assistant Professor in the Department of Mathematics and Statistics at Concordia University. His research interests are survival analysis, design and analysis of clinical trials and epidemiology. |
|
 |
|
| |
| Janet Dancey, MD, FRCP(C) |
Director, Translational Research – Clinical |
 |
|
In October 2008, Dr. Dancey took up her position as Director, Translational Research – Clinical. Prior to joining the NCIC CTG, Dr. Dancey was Senior Clinical Investigator in the Cancer Therapy Evaluation Program at the US National Cancer Institute and then Associate Chief of the Investigational Drug Branch. Dr. Dancey received her MD from the University of Ottawa and completed her residency training in internal medicine and medical oncology at the University of Toronto. In 1994-95, she was a research fellow with the NCIC CTG and continued her fellowship training at the Institut Gustave Roussy in France. Dr. Dancey has special expertise in new anti-cancer drug development, linking drug and biomarker development, and associated clinical trials methodology. |
|
| |
| Keyue Ding, PhD |
| Senior Biostatistician |
| Dr. Ding received his PhD in Statistics in 1999 from the University of Alberta, and subsequently did postdoctoral training in the Department of Biostatistics at the University of Rochester. He joined the NCIC Clinical Trials Group and Department of Community Health & Epidemiology at Queen's in 2001. As a Senior Biostatistician at NCIC Clinical Trials Group, his primary responsibilities are the design and analysis of the cancer clinical trials conducted by the Group. Dr. Ding is also interested in sequential analysis; statistical quality control procedures; and, statistical computing. |
|
 |
|
| |
| Christopher O'Callaghan, DVM, MSc, PhD, MRCVS |
| Project Coordinator |
 |
|
Dr. O'Callaghan received his Doctorate in Veterinary Medicine and MSc and PhD degrees from the University of Guelph. He became a Project Coordinator with the NCIC CTG in 2001 and oversees the Gastrointestinal and Brain Site Committees and is an Associate Professor in the Department of Community Health & Epidemiology. His research interests are diverse and include clinical trials design and methodology and infectious disease epidemiology. In addition to his duties with Queen's University and the NCIC CTG Dr. O'Callaghan is a member of the Provincial Infectious Diseases Advisor Committee (PIDAC) and the PIDAC Surveillance Subcommittee providing expert advice on infectious diseases to the Chief Medical Officer of Health for Ontario. |
|
| |
| Wendy R. Parulekar, MD, FRCP(C) |
| Physician Coordinator |
| Dr. Parulekar is a graduate of the University of Ottawa Medical School where she also completed residency training in Internal Medicine and Medical Oncology (1996). This was followed by a fellowship in Clinical Pharmacology at the Toronto-Sunnybrook Regional Cancer Centre. Since 1999, she has held a joint clinical/research position at Queen's University. Within the NCIC CTG, she acts as Physician Coordinator for national and international studies in melanoma, as well as carcinoma of the breast, head and neck, and genitourinary system. Other interests include issues relating to clinical trial design and conduct, as well as the challenges and opportunities in clinical trials involving developing nations. |
|
 |
|
| |
| Harriet Richardson, BSc, MSc, PhD |
| Project Coordinator |
 |
|
After receiving a Master's Degree in Virology at the University of Quebec, Dr. Richardson received a PhD in Epidemiology & Biostatistics at McGill University, where she studied the natural history of human papillomavirus infections and cervical neoplasia. She completed her postdoctoral fellowship with Dr. Kristan Aronson (CCE Div.) in 2004, working on several projects devoted to assessing the relationship between exposure to suspected carcinogens (both environmental and occupational) and the risk of certain cancers, including breast and lung cancer. In 2004, she accepted a position as Assistant Professor in the Department of Community Health & Epidemiology and joined the NCIC CTG where she is a project coordinator for clinical trials designed to evaluate the role of selected agents in chemoprevention. |
|
| |
| Lesley Seymour, MD, FCP (SA), FRCP(C), PhD |
| Co-Director IND |
| Dr. Seymour completed training in Internal Medicine, Clinical Haematology & Medical Oncology and went on to complete her PhD, focusing on correlative studies and breast cancer. She took the position of Director of Medical Oncology at the Newfoundland Cancer Treatment and Research Foundation. In 1996 she took up her current position as co-Director of the Investigational New Drug Program at the NCIC CTG, where her primary interests are in early drug development, novel inhibitors of signaling and the cell cycle, translational and pharmaco-dynamic studies in early clinical trials and clinical research in lung cancer. She also holds the position of Professor and Medical Oncologist in the Department of Oncology. |
|
 |
|
| |
| Lois Shepherd, MDCM, FRCP(C) |
| Physician Coordinator |
 |
|
Dr. Shepherd is a Professor in the Department of Pathology & Molecular Medicine. She completed her medical school training at McGill and spent three years in England where her interest in hematology developed. She completed her training as a Hematopathologist at the University of Ottawa and came to Kingston in 1987. Dr. Shepherd is currently the Director of the Transfusion Medicine Service & Immunology at Kingston General Hospital. Since 1989, Dr. Shepherd has worked with the NCIC CTG as a Physician Coordinator. Her focus has been in Haematology and Breast Cancer as well as the development of the National Tumor/Tissue Repositiory associated with the CTG and correlative studies in clinical trials. |
|
| |
| Jeremy Squire, MSc, PhD |
| Director, Translational Laboratory Research |
| Dr. Squire joined the NCIC CTG in June 2008 as Director, Translational Laboratory Research. His responsibilities within this role include leadership in facilitating the determination of strategic directions in translational research, engagement of basic and translational laboratory-based researchers from across Canada with NCIC CTG activities, and facilitation of these research activities at the Disease Site Committee level. Before coming to the NCIC CTG, Dr. Squire was the J. C. Boileau Grant Chair in Oncologic Pathology at the University of Toronto and a Senior Scientist in the Division of Applied Molecular Oncology at the Ontario Cancer Institute. Dr. Squire received his Bachelor of Science and Master’s degrees at the Queen Mary College, University of London. He completed his PhD in Medical Biophysics at the University of Toronto. |
|
 |
|
| |
| Dongsheng Tu, BSc, PhD |
| Senior Biostatistician |
 |
|
Dr. Tu is a Senior Biostatistician in the NCIC CTG with appointments in both the Departments of Community Health & Epidemiology, and Mathematics & Statistics. He came to Queen's in 1996 from the Therapeutic Products Directorate of Health Canada. His primary responsibilities are the design, management and analysis of the cancer clinical trials. He is also interested in the methodological research on the development and evaluation of statistical procedures for the design and analysis of cancer clinical trials and maintains an interest in the general mathematical theory of statistics. |
|
|
